Picture of Sinopharm logo

1099 — Sinopharm News Story

0.000.00%
hk flag iconLast trade - 00:00
HealthcareBalancedLarge CapContrarian

Sinopharm interim revenue edges down on softness in pharmaceutical distribution business

Sinopharm interim revenue edges down on softness in pharmaceutical distribution business


Overview

  • China pharmaceutical distributor's interim revenue declined slightly year-on-year

  • Net income attributable to shareholders fell compared to the prior-year period

  • Company focused on operational quality, risk management and digital transformation


Outlook

  • Sinopharm Group did not provide specific financial guidance for the current or future periods in the press release


Result Drivers

  • OPERATIONAL QUALITY FOCUS - Co said it concentrated on improving operational quality and efficiency in the first half

  • RISK MANAGEMENT - Sinopharm Group highlighted risk management and control as a key task during the reporting period

  • DIGITAL TRANSFORMATION - Co said it prioritized digital transformation as part of its strategic initiatives


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

H1 Revenue

RMB 282.80 bln

H1 Net Income Attributable

RMB 3.40 bln


Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 10 "strong buy" or "buy", 5 "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the pharmaceuticals peer group is "buy"

  • Wall Street's median 12-month price target for Sinopharm Group Co Ltd is HK$22.80, about 36.9% above its August 21 closing price of HK$16.65

  • The stock recently traded at 5 times the next 12-month earnings vs. a P/E of 6 three months ago


Reuters Recommended Reads

  • Aug 21 - China's Henlius H1 revenue jumps on drug sales, license income

  • Aug 21 - China's Haohai Biological H1 revenue falls, partly hurt by end of Brighten Optix distribution

  • Aug 20 - China's Brii Biosciences interim net loss narrows on lower R&D expenses


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Recent news on Sinopharm

See all news